Join the 'Vonvendi' group to help and get support from people like you.
FDA Approves Vonvendi [von Willebrand factor (recombinant)] for Perioperative Management of Bleeding in Adult Patients with von Willebrand Disease
Posted 7 May 2018 by Drugs.com
Cambridge, Ma. – April 17, 2018 – Shire plc (LSE: SHP, NASDAQ: SHPG), the global biotechnology leader in rare disease, today announced the U.S. Food and Drug Administration (FDA) has approved Vonvendi [von Willebrand factor (recombinant)], a recombinant von Willebrand factor (rVWF) treatment for perioperative management of bleeding in adults (age 18 and older) with von Willebrand disease (VWD).1 ...
Posted 12 Dec 2015 by Drugs.com
TUESDAY, Dec. 8, 2015 – Vonvendi has been approved to treat adults with von Willebrand disease (VWD), the most common inherited bleeding disorder. VWD, affecting about 1 percent of the U.S. population, is caused by lack of a protein that's essential for blood clotting. People with the disorder can develop severe bleeding from the nose, gums, intestines, muscles and joints. Women with VWD also ...
FDA Approves Vonvendi (Von Willebrand Factor (Recombinant)) to Treat Bleeding Episodes in Patients with VWD
Posted 10 Dec 2015 by Drugs.com
December 8, 2015 – The U.S. Food and Drug Administration today approved Vonvendi, von Willebrand factor (Recombinant), for use in adults 18 years of age and older who have von Willebrand disease (VWD). Vonvendi is the first FDA-approved recombinant von Willebrand factor, and is approved for the on-demand (as needed) treatment and control of bleeding episodes in adults diagnosed with VWD. VWD is ...